

Docket No.: P32181

PCT/EP99/08704

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE OF AN INSULIN SENSITISER
AND ANOTHER ANTIDIABETIC AGENT

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 8 November 1999 as Serial No. PCT/EP99/08704
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9824866.9	GB	12 November 1998	Yes
9824867.7	GB	12 November 1998	Yes
9824869.3	GB	12 November 1998	Yes
9912193.1	GB	25 May 1999	Yes
9912190.7	GB	25 May 1999	Yes
9912191.5	GB	25 May 1999	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available

Full Name of Inventor: Donald Colin MACKENZIE

Inventor's Signature: _____ Date: _____

Residence: HARLOW, ESSEX, GB

Citizenship: BRITISH

Post Office Address: GlaxoSmithKline
New Frontiers Science Park South
Third Avenue
Harlow
Essex CM19 5AW
United Kingdom

Full Name of Inventor: Vincenzo RE

Inventor's Signature: _____ Date: _____

Residence: HARLOW, ESSEX, GB

Citizenship: BRITISH

Post Office Address: GlaxoSmithKline
New Frontiers Science Park South
Third Avenue
Harlow
Essex CM19 5AW
United Kingdom

Docket No.: P32181

PCT/EP99/08704

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE OF AN INSULIN SENSITISER
AND ANOTHER ANTIDIABETIC AGENT

the specification of which (check one)

☐ is attached hereto.

☒ was filed on 8 November 1999 as Serial No. PCT/EP99/08704
and was amended on (if applicable).

I hereby state that I have reviewed and understand the content of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9824866.9	GB	12 November 1998	Yes
9824867.7	GB	12 November 1998	Yes
9824869.3	GB	12 November 1998	Yes
9912193.1	GB	25 May 1999	Yes
9912190.7	GB	25 May 1999	Yes
9912191.5	GB	25 May 1999	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number	Filing Date
--------------------	-------------

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available

between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to Yuriy P. Starcho, GlaxoSmithKline, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5018.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: Karen LEWIS

1-50 Inventor's Signature: *Karen Lewis* Date: 01 May 2007

Residence: HARLOW, ESSEX, GB

Citizenship: BRITISH GB³

Post Office Address: GlaxoSmithKline
New Frontiers Science Park South
Third Avenue
Harlow
Essex CM19 5AW
United Kingdom

Full Name of Inventor: Nicola Jayne LILLIOTT

Inventor's Signature: _____ Date: _____

Residence: ST ALBANS, HERTFORDSHIRE, GB

Citizenship: BRITISH

Post Office Address: c/o GlaxoSmithKline
New Frontiers Science Park South
Third Avenue
Harlow
Essex CM19 5AW
United Kingdom

between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 20462.

Address all correspondence and telephone calls to Yuriy P. Siercho, GlaxoSmithKline, Corporate Intellectual Property-U.S., UW2220, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939, whose telephone number is 610-270-5018.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued hereon.

Full Name of Inventor: Karen LEWIS

Inventor's Signature: _____ Date: _____

Residence: HARLOW, ESSEX, GB

Citizenship: BRITISH

Post Office Address: GlaxoSmithKline
New Frontiers Science Park South
Third Avenue
Harlow
Essex CM19 5AW
United Kingdom

2-00 Full Name of Inventor: Nicola Jayne LILLIOTT

Inventor's Signature: N. Lillio Date: 08 MAY 2001

Residence: ST ALBANS, HERTFORDSHIRE, GB

Citizenship: BRITISH

Post Office Address: c/o GlaxoSmithKline
New Frontiers Science Park South
Third Avenue
Harlow
Essex CM19 5AW
United Kingdom

GB3

3-00
Full Name of Inventor: Donald Colin MACKENZIEInventor's Signature: *Donald Mackenzie*Date: 01 MAY 2001Residence: HARLOW, ESSEX, GB GB3

Citizenship: BRITISH

Post Office Address: GlaxoSmithKline
New Frontiers Science Park South
Third Avenue
Harlow
Essex CM19 5AW
United Kingdom4-00
Full Name of Inventor: Vincenzo REInventor's Signature: *Vincenzo Re*Date: 1-MAY-2001Residence: HARLOW, ESSEX, GB GB3

Citizenship: BRITISH

Post Office Address: GlaxoSmithKline
New Frontiers Science Park South
Third Avenue
Harlow
Essex CM19 5AW
United Kingdom